Analysts Defend Questcor (QCOR) On Free-Fall In Shares

Article Stock Quotes (2) Comments (0)

Analysts are coming out to defend Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) with today's major sell-off after a negative research piece. However, at this point, it's to no avail.

Piper Jaffray reiterated their Outperform rating and $60 price target saying they do not believe generics are a risk. Even if filed, it would be a minimum 30 month stay. The firm specifically talked to Watson Pharmaceuticals, Inc. (NYSE: WPI), which said they have no plans to pursue filing for a generic version.

Shares of QCOR are down over 20 percent.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
• Pier 1 Imports (PIR) Sets Sights on Growing Ecommerce
• Potential 'Rip' Today in Transocean (RIG), Analyst has Eye on May $57.50 Calls

Create E-mail Alert Related Categories

Analyst Comments, Trader Talk

Related Entities

Piper Jaffray

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?